
Conversion of human glial cells into neurons in ex vivo culture of human brain tissue: essential roles of the transcription factors NeuroD1 and Ascl1
Brief intro:
- Author: Liang Xu, , Qingsong Wang, , Jiancheng Liao, , Jiajun Zheng, Bing Qin, , Wen Li, , Jiaxuan Zhang, , Wei Li, , Xiangyu Wang, , Maoying Zhang, , Gong Chen
- Journal: Neural Regeneration Research
- Publication Date: 2024 Dec 7
Abstract
Transcription factor–mediated cell conversion has been reported in the central nervous system of both rodents and nonhuman primates. In particular, glia-to-neuron conversion has been achieved in the brain and spinal cord of animal models for neural regeneration and repair. However, whether glia-to-neuron conversion can be used for brain repair in humans needs to be explored. To investigate the use of glia-to-neuron conversion technology in the human brain, we established a long-term ex vivo culture system using human brain tissue that was surgically removed from epileptic patients to test glia-to-neuron conversion directly. We found that neural transcription factors NeuroD1 and Ascl1 both converted human glial cells into neurons. Immunostaining and electrophysiological recordings showed that the glia-converted neurons demonstrated immature properties during the initial 7–14 days of conversion, and then acquired more mature neuronal properties after 21–27 days of conversion. These ex vivo conversion studies in human brain tissue pave the way toward future clinical trials using a transcription factor-based glia-to-neuron conversion approach to treat neurological disorders.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
